Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X:
“Tarlatamab in ES-SCLC (real-world).
n=27 relapsed
- ORR 18.2%; PFS 5.9 mo
- Intracranial control (RANO-BM): CR 2, PR 1, SD 9; no new CNS disease
- CRS ~40% (rare G≥3); ICANS 30% (↑ vs trials; 4 G≥3)
Signal of CNS efficacy with higher neurotoxicity.”
Title: Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity
Authors: Mitchell Parma, Kaiwen Wang, Ceylan Altintas Taslicay, Komal Shah, Eric K. Singhi, Melvin Rivera, Luisa Solis Soto, Wei-Lien Wang, Lingzhi Hong, Ziping Li, Mehmet Altan, Maria Franco Vega, Patricia de Groot, Alexa Halliday, Joshua Jacome, Jianjun Zhang, Xiuning Le, Jenny Pozadzides, Janet Tu, Celyne Bueno Hume, George Blumenschein, Ferdinandos Skoulidis, Tina Cascone, Frank Fossella, Marcelo Vailati Negrao, Natalie Vokes, Don Gibbons, Haniel Araujo, Anne Tsao, John Victor Heymach, Lauren Averett Byers, Carl Michael Gay and Bingnan Zhang
Other articles featuring Diego A. Díaz-García on OncoDaily.
